Oncotarget And The Development of Thyroid Cancer Cures

There are many articles today that you can read about Oncotarget, but many of them could probably be just write-ups that have nothing really good to say. Most of these articles are written by fledgling writers who are paid to do so.

In this article, we will address that and solve the issue by only offering you what we think you really need. We want to offer you the essentials. We want only to offer you the things that will be useful to you. How? Just read below for more of the info. Listen to Oncotarget podcast on Player.FM.

The Latest Report From ResearchGate

There are so many things happening in the research efforts of Oncotarget, but one of the latest and most updated things today would be the one about FOX06.

In the ResearchGate website, it is reported that one one of the many factors that contribute to FOXO genes and to carcinogenesis in the breast would have a lot to do with FOX06, which are the basic transcriptional factors in mammals.

There’s a lot of statistical analysis brought about by the study, and one of them would involve the role of FOXO family in understanding the roots of breast cancer. It is also in the research from ResearchGate about Oncotarget that you can read about the expression of breast cell lines and breast tumors in the human body. Listen to Oncotarget podcast on Stitcher.

Oncotarget’s Research on Thyroid Cancer

Other than the discussion on the role of FOXO gene expression, you may probably already heard about the involvement of Oncotarget in finding new therapies for thyroid cancer.

This new set of therapies from Oncotarget was reported from Eureka Alert, and in the report, it is shown through a Harvard Medical School report that an FDA-approved drug called palbociclib has been used as a breast cancer therapy for those who want to have better options. Cancer patients who need a respite from the drugs they’re taking that have been proven ineffective can see a lot of good from this new introduction presented by Oncotarget.

That said, there are so many things that can still be expected in thyroid cancer therapy, and it’s good to know that we have Oncotarget who will feature each and every one of them.

Follow: https://twitter.com/oncotargetjrnl?lang=en

Clay Siegall Efforts to Eliminate Cancer

Clay Siegall is the co-founder of Seattle Genetics. He is currently the CEO and a member of the board of directors of the company. Seattle Genetics is a biotechnology company with its headquarters in Bothell, Washington, United States. The company has been in operation since 1998. Seattle Genetics primary vision is to conduct research and develop various antibodies needed for cancer treatment therapies. With over twenty years’ experience in cancer research and cancer drugs development, Clay Siegall has aided a lot in the success of Seattle Genetics Company. Before co-founding Seattle Genetics, Mr. Siegall previously worked with various institutions like National Cancer Institute and the National Health Institute between 1988 and 1991, and later the Bristol Meyers Squibb Pharmaceutical Research Institute from 1991 to 1997.

Mr. Siegall has enabled the Seattle Genetics company to attain its current leadership position involving the production of Antibody-drug Conjugates (ADCs). In 2011, Mr. Siegall helped the company secure Food and Drugs Administration (FDA) approval for ADCETRIS (brentuximab vedotin), its first ADC product. ADCETRIS is a drug designed to help prevent complications arising as a result of cancer therapies. Since then, ADCETRIS has been in use in more than sixty countries worldwide. Mr. Siegall has also aided in the Seattle Genetics’ revenue raising activities. He has secured billions through both public and private financing.

Several media outlets have featured Clay Siegall. In May 2015, Seaport World Trade Center’s Pegs Boston interviewed Mr. Siegall about the future of Seattle Genetics and the ADECTRIS drug. The interview happened before the release of ADC drug by FDA. Later on, in September 2016, a report by Hackryonm indicated that indeed Seattle Genetics had received a stamp of approval for the ADC drug. Mr. Siegall is a man driven by desire to find the cure for cancer, a disease that consumes thousands of lives annually. His company is frequently advancing in the production of more potent antibodies that aid in attacking cancer cells.